CN108295095A - Purposes and its drug/composite skin care product of the Lyopgized Nocardia rubra-cell Wall Skeleton in the drug/skin care item for preparing treatment acne - Google Patents

Abstract

The invention discloses purposes of the Lyopgized Nocardia rubra-cell Wall Skeleton in the drug and skin care item for preparing treatment acne；And provide drug/composite skin care product of the treatment acne containing Lyopgized Nocardia rubra-cell Wall Skeleton.Lyopgized Nocardia rubra-cell Wall Skeleton is applied to the treatment of acne by the present invention, the various clinical symptoms of acne can effectively be treated, including acne print caused by blackhead, Whiteheads, inflamed papules, warts, tubercle, tumour and acne, and safety is good, has no stimulation of the skin.

Description

Application of nocardia rubra cell wall skeleton in preparation of medicine/skin care product for treating acne and medicine/skin care product composition thereof

Technical Field

The invention relates to the field of medicines and skin care products, in particular to application of nocardia rubra cell wall skeleton in preparing medicines/skin care products for treating acne and a medicine/skin care product composition thereof.

Background

Acne, commonly known as whelk, comedo and pimple, is a chronic skin disease occurring in pilosebaceous glands, and statistically 95% of adolescent men and 85% of adolescent women suffer from acne of different degrees. The main clinical manifestations of acne are blackheads, whiteheads, inflammatory papules, pustules, nodules and cysts, which are prone to pigmentation, large pores and even scar-like damage, and most of the acne occurs in the rich sebaceous glands of the head, face, neck, chest and back, etc., and severe acne can lead to disfigurement.

At present, the active ingredient of the acne treatment medicament is salicylic acid which is fat-soluble hydroxy acid and can permeate into pores to dissolve dead skin cells blocking the pores and clear the pores. However, salicylic acid can only maintain a relatively ideal solubility at a pH of 3-4, and thus salicylic acid formulations have undesirable side effects which can cause skin dryness, irritation, allergy, and the like. It is very necessary to develop a new medicament or skin care product for treating acne and acne marks.

Disclosure of Invention

The object of the present invention is to provide a novel method for treating acne with good safety and without skin irritation.

In order to achieve the above object, the present invention provides the use of a nocardia rubra cell wall scaffold in the preparation of a medicament for the treatment of acne; simultaneously provides the application of the nocardia rubra cell wall skeleton in preparing the skin care product for improving the acne.

The invention also provides a pharmaceutical composition or a skin care product for treating acne, wherein the pharmaceutical composition or the skin care product contains the nocardia rubra cell wall skeleton and auxiliary components; the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (300-9999); preferably, the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (300-4999).

The Nocardia rubra cell wall skeleton is obtained by fermenting, crushing and extracting Nocardia rubra cell wall skeleton (N-CWS), mainly contains components of the cell wall, such as mycolic acid, arabinogalactan, mucopeptide and the like, and does not contain preservatives and antibiotics. The nocardia rubra cell wall skeleton can be prepared by conventional fermentation, crushing and extraction technologies.

Through the technical scheme, the nocardia rubra cell wall skeleton is applied to the treatment of the acne, various clinical symptoms of the acne can be effectively treated, including comedones, inflammatory papules, pustules, nodules, cysts and acne-caused acne marks, and the nocardia rubra cell wall skeleton has high safety and no stimulation to skin.

Additional features and advantages of the invention will be set forth in the detailed description which follows.

Detailed Description

The following describes in detail specific embodiments of the present invention. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.

In a first aspect, the present invention provides the use of a nocardia rubra cell wall scaffold in the manufacture of a medicament for the treatment of acne or a skin care product for the amelioration of acne.

The Nocardia rubra cell wall skeleton is obtained by fermenting, crushing and extracting Nocardia rubra cell wall skeleton (N-CWS), mainly contains components of the cell wall, such as mycolic acid, arabinogalactan, mucopeptide and the like, and does not contain preservatives and antibiotics. The nocardia rubra cell wall skeleton can be prepared by conventional fermentation, crushing and extraction technologies.

Through the technical scheme, the nocardia rubra cell wall skeleton is applied to the treatment of the acne, various clinical symptoms of the acne can be effectively treated, the safety is good, and no stimulation is caused to the skin.

According to the first aspect of the present invention, the acne includes blackheads, whiteheads, inflammatory papules, pustules, nodules, cysts, acne-caused acne marks and other clinical symptoms.

According to the first aspect of the present invention, the medicament or skin care product of the present invention can be prepared into various common pharmaceutical dosage forms for external use by conventional methods, such as aqueous solution, aerosol, spray, emulsion, ointment, gel or lyophilized powder; the skin care product is facial cleanser, astringent, essence, lotion or cream.

According to the first aspect of the present invention, in order to maintain the stability of the drug, an auxiliary component is added to the nocardia rubra cell wall skeleton; meanwhile, in order to keep the drug lasting and effective, the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (300-9999); preferably, the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (1999-4999).

Various auxiliary ingredients may be preferably used depending on the dosage form of the pharmaceutical composition of the present invention; the auxiliary components may be used in various materials conventionally used by those skilled in the art, and the present invention is not particularly limited thereto.

In the pharmaceutical composition, the auxiliary component comprises at least one of a matrix, a propellant, a humectant, a solvent, a solubilizer, an emulsifier, an antioxidant, a pH regulator and a preservative; the matrix is at least one of white vaseline, carbomer, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, chitosan, sucralfate chitosan polyvinylpyrrolidone, polyvinyl alcohol and sodium hyaluronate; the propellant is selected from at least one of dimethyl ether, tetrafluoroethane and hydrofluoroalkane; the humectant is selected from at least one of glycerin and propylene glycol; the solvent is at least one selected from deionized water, distilled water, ethanol, hexadecanol, octadecanol, p-aminobenzoic acid, acetamide and isopropanol; the solubilizer is selected from at least one of tween-60, tween-80 and polyoxyethylene hydrogenated castor oil; the emulsifier is at least one selected from stearic acid, glyceryl monostearate, triglycerol monostearate, sucrose fatty acid ester, sucrose acetate isobutyrate, sorbitan tristearate, isopropyl myristate, cholesterol, squalene, squalane, n-butanol, ethylene glycol, ethanol, propylene glycol and polyglycerol ester; the antioxidant is selected from at least one of sulfite, cysteine, di-tert-butyl hydroxy toluene and potassium sorbate; the pH regulator is at least one selected from phosphoric acid buffer solution, triethanolamine, sodium hydroxide, ethylenediamine, laurylamine, sodium bicarbonate and hydrochloric acid; the preservative is selected from at least one of parabens, thimerosal, chlorocresol, trichloro-tert-butanol and benzoic acid and sodium salt thereof; the nocardia rubra cell wall skeleton, the matrix, the propellant, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative are in a weight ratio of 1: (0.1-1000): (0.1-1000): (0.1-7000): (100-10000): (0.1-2000): (0.1-1000): (0.01-30000): (0.1-1000);

or, in the skin care product, the auxiliary component comprises at least one of a matrix, a humectant, a solvent, an emulsifier, an antioxidant, a pH regulator and a preservative; the matrix is at least one of carbomer, polyethylene glycol, polysorbate, propylene glycol, butylene glycol, hexylene glycol and isopropyl myristate; the humectant is at least one selected from glycerol, sorbitol, mannitol, xylitol, squalane and squalene; the solvent is at least one selected from deionized water, distilled water, ethanol, butanol, pentanol and isopropanol; the emulsifier is at least one selected from vaseline, white oil, silicone oil and lanolin; the antioxidant is at least one selected from sulfite, di-tert-butyl hydroxy toluene and potassium sorbate; the pH regulator is at least one selected from triethanolamine, sodium hydroxide, ethylenediamine, laurylamine, sodium bicarbonate and hydrochloric acid; the preservative is selected from at least one of parabens, propylene glycol, cason, jeep horse power and benzoic acid and its sodium salt; the nocardia rubra cell wall skeleton, the matrix, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative are in a weight ratio of 1: (0.1-1000): (0.1-700): (100-10000): (0.1-2000): (0.1-1000): (0.1-3000): (0.1-1000).

Preferably, the first and second electrodes are formed of a metal,

in the pharmaceutical composition, the weight ratio of the nocardia rubra cell wall skeleton, the matrix, the propellant, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative is 1: (20-300): (40-1000): (60-500): (1400-4750): (40-1000): (2-20): (100-2000): (2-30);

or, in the skin care product, the weight ratio of the nocardia rubra cell wall skeleton, the matrix, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative is 1: (20-300): (60-500): (1400-4750): (40-1000): (2-20): (100-2000): (2-30).

As the best mode of the present disclosure, the total weight of the pharmaceutical or skin care composition is 100%, wherein,

the pharmaceutical composition contains 0.01 to 0.3 weight percent of nocardia rubra cell wall skeleton, 0.01 to 2 weight percent of tween-80, 1 to 4 weight percent of isopropyl myristate, 0.01 to 2 weight percent of p-aminobenzoic acid, 0.01 to 2 weight percent of squalene, 0.01 to 5 weight percent of stearic acid, 1 to 5 weight percent of glycerol, 0.1 to 5 weight percent of hexadecanol, 1 to 10 weight percent of tetrafluoroethane, 1 to 10 weight percent of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent, and can be prepared into the aerosol of the nocardia rubra cell wall skeleton.

Or the pharmaceutical composition contains 0.01 to 0.3 weight percent of nocardia rubra cell wall skeleton, 0.5 to 2 weight percent of carbomer, 0.05 to 2 weight percent of tween-80, 0.01 to 1 weight percent of benzoic acid, 0.02 to 2 weight percent of sodium sulfite, 1 to 8 weight percent of glycerol, 1 to 10 weight percent of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent, and the gel of the nocardia rubra cell wall skeleton can be prepared.

Or the pharmaceutical composition contains 0.01 to 0.3 weight percent of nocardia rubra cell wall skeleton, 1 to 5 weight percent of white vaseline, 0.1 to 2 weight percent of tween-80, 0.01 to 1 weight percent of benzoic acid, 0.02 to 2 weight percent of sodium sulfite, 1 to 8 weight percent of glycerol, 0.01 to 2 weight percent of squalene, 1 to 10 weight percent of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent, and the emulsion of the nocardia rubra cell wall skeleton can be prepared.

The skin care product composition contains 0.01-0.3 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 1-8 wt% of glycerol, 3-10 wt% of lanolin, 0.02-2 wt% of squalene, 1-10 wt% of sodium hydroxide solution with the concentration of 1% (W/V) and the balance of solvent, and the emulsion containing the nocardia rubra cell wall skeleton and used for improving acne can be prepared.

Or the skin care product composition contains 0.01-0.3 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 0.5-2 wt% of carbomer, 3-8 wt% of glycerol, 1-10 wt% of sodium hydroxide solution with the concentration of 1% (W/V) and the balance of solvent, and the acne-improving essence containing the nocardia rubra cell wall skeleton can be prepared.

Or the skin care composition contains 0.01 to 0.3 weight percent of nocardia rubra cell wall skeleton, 0.01 to 1 weight percent of benzoic acid, 0.02 to 2 weight percent of sodium sulfite, 5 to 10 weight percent of lanolin, 0.02 to 2 weight percent of squalene, 10 to 20 weight percent of polysorbate, 1 to 10 weight percent of 1% (W/V) sodium hydroxide solution and the balance of solvent, and the cream for improving acne containing the nocardia rubra cell wall skeleton can be prepared.

In a second aspect of the present invention, a pharmaceutical composition or a skin care product for treating acne is provided, wherein the pharmaceutical composition or the skin care product may contain nocardia rubra cell wall skeleton and auxiliary components; the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (300-9999); preferably, the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (1999-4999).

According to the second aspect of the present invention, the dosage form of the pharmaceutical composition may be various dosage forms commonly used in the art; for example, the pharmaceutical composition is in the form of a liquid, aerosol, spray, emulsion, paste, gel or lyophilized powder; the skin care product is facial cleanser, astringent, essence, lotion or cream.

Various auxiliary components can be adopted according to different dosage forms of the pharmaceutical composition; the auxiliary components may be used in various materials conventionally used by those skilled in the art, and the present invention is not particularly limited thereto.

In the pharmaceutical composition, the auxiliary component comprises at least one of a matrix, a propellant, a humectant, a solvent, a solubilizer, an emulsifier, an antioxidant, a pH regulator and a preservative; the matrix is at least one of white vaseline, carbomer, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, chitosan, sucralfate chitosan polyvinylpyrrolidone, polyvinyl alcohol and sodium hyaluronate; the propellant is selected from at least one of dimethyl ether, tetrafluoroethane and hydrofluoroalkane; the humectant is selected from at least one of glycerin and propylene glycol; the solvent is at least one selected from deionized water, distilled water, ethanol, hexadecanol, octadecanol, p-aminobenzoic acid, acetamide and isopropanol; the solubilizer is selected from at least one of tween-60, tween-80 and polyoxyethylene hydrogenated castor oil; the emulsifier is at least one selected from stearic acid, glyceryl monostearate, triglycerol monostearate, sucrose fatty acid ester, sucrose acetate isobutyrate, sorbitan tristearate, isopropyl myristate, cholesterol, squalene, squalane, n-butanol, ethylene glycol, ethanol, propylene glycol and polyglycerol ester; the antioxidant is selected from at least one of sulfite, cysteine, di-tert-butyl hydroxy toluene and potassium sorbate; the pH regulator is at least one selected from phosphoric acid buffer solution, triethanolamine, sodium hydroxide, ethylenediamine, laurylamine, sodium bicarbonate and hydrochloric acid; the preservative is selected from at least one of parabens, thimerosal, chlorocresol, trichloro-tert-butanol and benzoic acid and sodium salt thereof; the nocardia rubra cell wall skeleton, the matrix, the propellant, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative are in a weight ratio of 1: (0.1-1000): (0.1-1000): (0.1-7000): (100-10000): (0.1-2000): (0.1-1000): (0.01-30000): (0.1-1000);

or,

in the skin care product, the auxiliary ingredients comprise at least one of a matrix, a humectant, a solvent, an emulsifier, an antioxidant, a pH regulator and a preservative; the matrix is at least one of carbomer, polyethylene glycol, polysorbate, propylene glycol, butylene glycol, hexylene glycol and isopropyl myristate; the humectant is at least one selected from glycerol, sorbitol, mannitol, xylitol, squalane and squalene; the solvent is at least one selected from deionized water, distilled water, ethanol, butanol, pentanol and isopropanol; the emulsifier is at least one selected from vaseline, white oil, silicone oil and lanolin; the antioxidant is at least one selected from sulfite, di-tert-butyl hydroxy toluene and potassium sorbate; the pH regulator is at least one selected from triethanolamine, sodium hydroxide, ethylenediamine, laurylamine, sodium bicarbonate and hydrochloric acid; the preservative is selected from at least one of parabens, propylene glycol, cason, jeep horse power and benzoic acid and its sodium salt; the nocardia rubra cell wall skeleton, the matrix, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative are in a weight ratio of 1: (0.1-1000): (0.1-700): (100-10000): (0.1-2000): (0.1-1000): (0.1-3000): (0.1-1000).

Preferably, the first and second electrodes are formed of a metal,

in the pharmaceutical composition, the weight ratio of the nocardia rubra cell wall skeleton, the matrix, the propellant, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative is 1: (20-300): (40-1000): (60-500): (1400-4750): (40-1000): (2-20): (100-2000): (2-30);

or, in the skin care product, the weight ratio of the nocardia rubra cell wall skeleton, the matrix, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative is 1: (20-300): (60-500): (1400-4750): (40-1000): (2-20): (100-2000): (2-30).

As the best mode of the present disclosure, the total weight of the pharmaceutical or skin care composition is 100%, wherein,

the pharmaceutical composition contains 0.01 to 0.3 weight percent of nocardia rubra cell wall skeleton, 0.01 to 2 weight percent of tween-80, 1 to 4 weight percent of isopropyl myristate, 0.01 to 2 weight percent of p-aminobenzoic acid, 0.01 to 2 weight percent of squalene, 0.01 to 5 weight percent of stearic acid, 1 to 5 weight percent of glycerol, 0.1 to 5 weight percent of hexadecanol, 1 to 10 weight percent of tetrafluoroethane, 1 to 10 weight percent of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent, and can be prepared into the aerosol of the nocardia rubra cell wall skeleton.

Or the pharmaceutical composition contains 0.01 to 0.3 weight percent of nocardia rubra cell wall skeleton, 0.5 to 2 weight percent of carbomer, 0.05 to 2 weight percent of tween-80, 0.01 to 1 weight percent of benzoic acid, 0.02 to 2 weight percent of sodium sulfite, 1 to 8 weight percent of glycerol, 1 to 10 weight percent of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent, and the gel of the nocardia rubra cell wall skeleton can be prepared.

Or the pharmaceutical composition contains 0.01 to 0.3 weight percent of nocardia rubra cell wall skeleton, 1 to 5 weight percent of white vaseline, 0.1 to 2 weight percent of tween-80, 0.01 to 1 weight percent of benzoic acid, 0.02 to 2 weight percent of sodium sulfite, 1 to 8 weight percent of glycerol, 0.01 to 2 weight percent of squalene, 1 to 10 weight percent of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent, and the emulsion of the nocardia rubra cell wall skeleton can be prepared.

The skin care product composition contains 0.01-0.3 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 1-8 wt% of glycerol, 3-10 wt% of lanolin, 0.02-2 wt% of squalene, 1-10 wt% of sodium hydroxide solution with the concentration of 1% (W/V) and the balance of solvent, and the emulsion containing the nocardia rubra cell wall skeleton and used for improving acne can be prepared.

Or the skin care product composition contains 0.01-0.3 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 0.5-2 wt% of carbomer, 3-8 wt% of glycerol, 1-10 wt% of sodium hydroxide solution with the concentration of 1% (W/V) and the balance of solvent, and the acne-improving essence containing the nocardia rubra cell wall skeleton can be prepared.

Or the skin care composition contains 0.01 to 0.3 weight percent of nocardia rubra cell wall skeleton, 0.01 to 1 weight percent of benzoic acid, 0.02 to 2 weight percent of sodium sulfite, 5 to 10 weight percent of lanolin, 0.02 to 2 weight percent of squalene, 10 to 20 weight percent of polysorbate, 1 to 10 weight percent of 1% (W/V) sodium hydroxide solution and the balance of solvent, and the cream for improving acne containing the nocardia rubra cell wall skeleton can be prepared.

Through the technical scheme, the nocardia rubra cell wall skeleton is applied to improving acne, various clinical symptoms of the acne can be effectively treated, the safety is good, and no stimulation is caused to skin.

The invention is further illustrated by the following examples, but is not to be construed as being limited thereto.

The nocardia rubra cell wall skeleton is prepared and produced by Shanhe pharmaceutical industry Co.

Example 1

The skin care composition is prepared by the following steps: first, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, glycerol, lanolin, squalene and part of distilled water are uniformly mixed, the pH is adjusted to 7 by using 1% (w/v) sodium hydroxide solution, and the rest of distilled water is added, wherein the material is added in such an amount that the mixed material contains 0.01 wt% of nocardia rubra cell wall skeleton, 0.1 wt% of benzoic acid, 0.2 wt% of sodium sulfite, 5 wt% of glycerol, 4 wt% of lanolin and 0.2 wt% of squalene. Stirring the mixed materials at the speed of 50 revolutions per minute for 10 minutes to prepare 0.01 weight percent of red nocardia rubra cell wall skeleton skin care emulsion.

Example 2

The skin care composition is prepared by the following steps: first, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, carbomer, glycerol, ethanol and part of distilled water are uniformly mixed, the pH is adjusted to 7 by using 1% (w/v) sodium hydroxide solution, and the rest distilled water is added, wherein the material dosage of the materials is that the mixed material contains 0.1 weight percent of nocardia rubra cell wall skeleton, 0.1 weight percent of benzoic acid, 0.2 weight percent of sodium sulfite, 1.5 weight percent of carbomer, 5 weight percent of glycerol and 20 weight percent of ethanol. Stirring the mixed materials at the speed of 50 revolutions per minute for 10 minutes to prepare 0.1 weight percent of red nocardia rubra cell wall skeleton skin care essence.

Example 3

The skin care composition is prepared by the following steps: first, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, lanolin, squalene, polysorbate and part of distilled water are mixed uniformly, pH is adjusted to 7 by using 1% (w/v) sodium hydroxide solution, and the rest of distilled water is added, wherein the above materials are fed in such amounts that the mixed material contains nocardia rubra cell wall skeleton of 0.3 wt%, benzoic acid of 0.1 wt%, sodium sulfite of 0.2 wt%, lanolin of 10 wt%, squalene of 0.2 wt%, and polysorbate of 15 wt%. The above mixed materials were stirred at a rate of 20 rpm for 10 minutes to prepare 0.3 wt% nocardia rubra cell wall skeleton cream.

Example 4

The pharmaceutical composition is prepared by the following steps: firstly, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, carbomer, tween-80, glycerol and part of distilled water are uniformly mixed, the pH is adjusted to 7 by using a phosphoric acid buffer solution with the value of 0.1M, pH being 7.2, and the rest distilled water is added, wherein the material feeding amount of the materials is that the mixed material contains 0.1 weight percent of nocardia rubra cell wall skeleton, 1.5 weight percent of carbomer, 0.1 weight percent of tween-80, 0.1 weight percent of benzoic acid, 0.2 weight percent of sodium sulfite and 5 weight percent of glycerol. The mixed materials are stirred for 10 minutes at the speed of 50 revolutions per minute to prepare 0.1 weight percent nocardia rubra cell wall skeleton gel.

Example 5

The pharmaceutical composition is prepared by the following steps: firstly, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, white vaseline, lanolin, tween-80, glycerol, squalene and part of distilled water are uniformly mixed, the pH value is adjusted to 7 by using a phosphoric acid buffer solution with the pH value of 7.2 of 0.1M, and the rest of distilled water is added, wherein the material adding amount of each material is that the mixed material contains 0.3 weight percent of nocardia rubra cell wall skeleton, 3 weight percent of white vaseline, 5 weight percent of lanolin, 0.1 weight percent of tween-80, 0.1 weight percent of benzoic acid, 0.2 weight percent of sodium sulfite, 5 weight percent of glycerol and 0.2 weight percent of squalene. The above mixed materials were stirred at a rate of 50 rpm for 10 minutes to prepare a 0.5 wt% nocardia rubra cell wall skeleton emulsion.

Example 6

The pharmaceutical composition is prepared by the following steps: first, nocardia rubra cell wall skeleton, tween-80, isopropyl myristate, p-aminobenzoic acid, squalene, stearic acid, glycerol, cetyl alcohol, tetrafluoroethane and part of distilled water are uniformly mixed, the pH is adjusted to 7 by using a phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2, and the rest of distilled water is added, wherein the material is added in such an amount that the mixed material contains 0.03 wt% of nocardia rubra cell wall skeleton, 0.1 wt% of tween-80, 5 wt% of isopropyl myristate, 0.2 wt% of p-aminobenzoic acid, 0.1 wt% of squalene, 3 wt% of stearic acid, 3.7 wt% of glycerol, 1 wt% of cetyl alcohol and 5 wt% of tetrafluoroethane. Stirring the above mixture at a speed of 50 rpm for 10 minutes to obtain 0.03 wt% nocardia rubra cell wall skeleton medicament, and filling into an aerosol bottle to obtain aerosol.

Example 7

The pharmaceutical composition is prepared by the following steps: firstly, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, white vaseline, lanolin, tween-80, glycerol, squalene and part of distilled water are uniformly mixed, the pH value is adjusted to 7 by using a phosphoric acid buffer solution with the pH value of 7.2 of 0.1M, and the rest of distilled water is added, wherein the material adding amount of each material is that the mixed material contains 0.05 weight percent of nocardia rubra cell wall skeleton, 3 weight percent of white vaseline, 5 weight percent of lanolin, 0.1 weight percent of tween-80, 0.1 weight percent of benzoic acid, 0.2 weight percent of sodium sulfite, 5 weight percent of glycerol and 0.2 weight percent of squalene. The above mixed materials were stirred at a rate of 50 rpm for 10 minutes to prepare a 0.05 wt% nocardia rubra cell wall skeleton emulsion.

Example 8

The pharmaceutical composition is prepared by the following steps: firstly, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, white vaseline, lanolin, tween-80, glycerol, squalene and part of distilled water are uniformly mixed, the pH value is adjusted to 7 by using a phosphoric acid buffer solution with the pH value of 7.2 of 0.1M, and the rest of distilled water is added, wherein the material adding amount of each material is that the mixed material contains 0.04 wt% of nocardia rubra cell wall skeleton, 3 wt% of white vaseline, 5 wt% of lanolin, 0.1 wt% of tween-80, 0.1 wt% of benzoic acid, 0.2 wt% of sodium sulfite, 5 wt% of glycerol and 0.2 wt% of squalene. The above mixed materials were stirred at a rate of 50 rpm for 10 minutes to prepare a 0.04 wt% nocardia rubra cell wall skeleton emulsion.

Example 9

The pharmaceutical composition is prepared by the following steps: firstly, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, white vaseline, lanolin, tween-80, glycerol, squalene and part of distilled water are uniformly mixed, the pH value is adjusted to 7 by using a phosphoric acid buffer solution with the pH value of 7.2 of 0.1M, and the rest of distilled water is added, wherein the material adding amount of each material is that the mixed material contains 0.03 weight percent of nocardia rubra cell wall skeleton, 3 weight percent of white vaseline, 5 weight percent of lanolin, 0.1 weight percent of tween-80, 0.1 weight percent of benzoic acid, 0.2 weight percent of sodium sulfite, 5 weight percent of glycerol and 0.2 weight percent of squalene. The above mixed materials were stirred at a rate of 50 rpm for 10 minutes to prepare a 0.03 wt% nocardia rubra cell wall skeleton emulsion.

Example 10

The pharmaceutical composition is prepared by the following steps: firstly, nocardia rubra cell wall skeleton, benzoic acid, sodium sulfite, white vaseline, lanolin, tween-80, glycerol, squalene and part of distilled water are uniformly mixed, the pH value is adjusted to 7 by using a phosphoric acid buffer solution with the pH value of 7.2 of 0.1M, and the rest of distilled water is added, wherein the material adding amount of each material is that the mixed material contains 0.02 wt% of nocardia rubra cell wall skeleton, 3 wt% of white vaseline, 5 wt% of lanolin, 0.1 wt% of tween-80, 0.1 wt% of benzoic acid, 0.2 wt% of sodium sulfite, 5 wt% of glycerol and 0.2 wt% of squalene. The above mixed materials were stirred at a rate of 50 rpm for 10 minutes to prepare a 0.02 wt% nocardia rubra cell wall skeleton emulsion.

Comparative example 1

The pharmaceutical composition is prepared by the following steps: salicylic acid, benzoic acid, sodium sulfite, white vaseline, lanolin, tween-80, glycerol, squalene and part of distilled water are uniformly mixed, the pH is adjusted to 7 by using a phosphoric acid buffer solution with the pH value of 7.2 of 0.1M, and the rest of distilled water is added, wherein the material amount of each material is such that the mixed material contains 1 wt% of salicylic acid, 3 wt% of white vaseline, 5 wt% of lanolin, 0.1 wt% of tween-80, 0.1 wt% of benzoic acid, 0.2 wt% of sodium sulfite, 5 wt% of glycerol and 0.2 wt% of squalene. The above mixed materials are stirred for 10 minutes at the speed of 50 revolutions per minute to prepare the salicylic acid emulsion.

Comparative example 2

The pharmaceutical composition is prepared by the following steps: firstly, viaminate, vitamin E, benzoic acid, sodium sulfite, white vaseline, lanolin, Tween-80, glycerol, squalene and part of distilled water are uniformly mixed, the pH value is adjusted to 7 by using a phosphoric acid buffer solution with the pH value of 7.2 of 0.1M, and the rest of distilled water is added, wherein the above materials are fed in such amounts that the mixed material contains 0.4 wt% of viaminate, 0.6 wt% of vitamin E, 3 wt% of white vaseline, 5 wt% of lanolin, 0.1 wt% of Tween-80, 0.1 wt% of benzoic acid, 0.2 wt% of sodium sulfite, 5 wt% of glycerol and 0.2 wt% of squalene. The mixed materials are stirred for 10 minutes at the speed of 50 revolutions per minute to prepare the viaminate vitamin E emulsion.

Comparative example 3

The pharmaceutical composition is prepared by the following steps: first, inactivated corynebacterium parvum, benzoic acid, sodium sulfite, white vaseline, lanolin, tween-80, glycerol, squalene and a part of distilled water were uniformly mixed, pH was adjusted to 7 using a phosphoric acid buffer solution of 0.1M and pH 7.2, and the remaining distilled water was added in such amounts that the mixed material contained 1 wt% of inactivated corynebacterium parvum, 3 wt% of white vaseline, 5 wt% of lanolin, 0.1 wt% of tween-80, 0.1 wt% of benzoic acid, 0.2 wt% of sodium sulfite, 5 wt% of glycerol, and 0.2 wt% of squalene. The inactivated corynebacterium parvum emulsion is prepared by stirring the mixed materials at the speed of 50 revolutions per minute for 10 minutes.

Comparative example 4

The pharmaceutical composition is prepared by the following steps: first, candida, benzoic acid, sodium sulfite, white vaseline, lanolin, tween-80, glycerol, squalene and part of distilled water are uniformly mixed, the pH is adjusted to 7 by using a phosphoric acid buffer solution with the pH value of 7.2 of 0.1M, and the rest of distilled water is added, wherein the addition amount of each material is that the mixed material contains 1 wt% of candida, 3 wt% of white vaseline, 5 wt% of lanolin, 0.1 wt% of tween-80, 0.1 wt% of benzoic acid, 0.2 wt% of sodium sulfite, 5 wt% of glycerol and 0.2 wt% of squalene. The mixed materials are stirred for 10 minutes at the speed of 50 r/min to prepare the candida emulsion.

Test example 1

This test example 1 was used to examine the use comfort and the treatment effect on acne of the skin care products prepared in examples 1 to 3, the medicines prepared in examples 4 to 10 and comparative examples 1 to 4.

First, 40 patients with acne on the face of 15-35 years old were divided into 8 groups of 5, and the skin-care products prepared in examples 1-3, the drugs prepared in examples 4-10 and comparative examples 1-4 were applied to the face of 50mg of the drug/skin-care composition 1 time each day in the morning and evening for 30 days, respectively, and the acne condition before and after use was recorded. The acne grading criteria used in the test examples were: (1) grade 1 clinical manifestations are acne, a small number of papules and pustules, with a total lesion count of less than 30; (2) the grade 2 clinical manifestations are acne, moderate and equal amounts of papules and pustules, and the total number of lesions is between 31 and 50; (3) the grade 3 clinical manifestations are a large number of papules and pustules, occasionally large inflammatory lesions, widely distributed, the total number of lesions is 51-100, and the number of nodules is less than 3; (4) the grade 4 clinical manifestations are nodular, cystic or conglobate acne, most of which have pain and form cysts and sinuses, the total number of lesions is more than 100, and the number of nodules or cysts is more than 3. The use comfort of the medicine and the skin care product is evaluated according to the use feeling of the subject; where "+" indicates comfort, "+/-" indicates no sensation and "-" indicates discomfort, the results are shown in table 1. The improvement effect was calculated by the average grade of acne in 5 participants before and after use, and the improvement effect was calculated by formula (1), and the specific results are shown in table 2.

Improvement effect [ before use (stage) -after use (stage) ]/before use (stage) formula (1)

TABLE 1

TABLE 2

As can be seen from comparison of examples 1-10 with comparative examples 1-4 in tables 1-2, the application of the nocardia rubra cell wall skeleton in the treatment of acne can effectively treat various clinical symptoms of acne, and has the advantages of good safety and no irritation to skin. Furthermore, as can be seen by comparing examples 4-5 with examples 6-10, in the preferred embodiment of the present invention, the weight ratio of nocardia rubra cell wall skeleton to the auxiliary components is 1: (1999-4999), has better acne treatment effect.

The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.

It should be noted that the various features described in the above embodiments may be combined in any suitable manner without departing from the scope of the invention. The invention is not described in detail in order to avoid unnecessary repetition.

In addition, any combination of the various embodiments of the present invention is also possible, and the same should be considered as the disclosure of the present invention as long as it does not depart from the spirit of the present invention.

Claims (10)

1. Use of a nocardia rubra cell wall skeleton for the preparation of a pharmaceutical composition for the treatment of acne or a skin care product for the amelioration of acne.

2. The use of claim 1, wherein the acne comprises at least one of blackheads, whiteheads, inflammatory papules, pustules, nodules, cysts, and acne-induced pox marks.

3. The use of claim 1, wherein the pharmaceutical composition is in the form of a liquid, aerosol, spray, emulsion, cream, gel or lyophilized powder; the skin care product is facial cleanser, astringent, essence, lotion or cream.

4. The use according to claim 1 or 2, wherein the pharmaceutical composition or the skin care product comprises nocardia rubra cell wall skeleton and auxiliary components; the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (300-9999); preferably, the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (1999-4999).

5. The use according to claim 4, wherein,

in the pharmaceutical composition, the auxiliary component comprises at least one of a matrix, a propellant, a humectant, a solvent, a solubilizer, an emulsifier, an antioxidant, a pH regulator and a preservative; the matrix is at least one of white vaseline, carbomer, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, chitosan, sucralfate chitosan polyvinylpyrrolidone, polyvinyl alcohol and sodium hyaluronate; the propellant is selected from at least one of dimethyl ether, tetrafluoroethane and hydrofluoroalkane; the humectant is selected from at least one of glycerin and propylene glycol; the solvent is at least one selected from deionized water, distilled water, ethanol, hexadecanol, octadecanol, p-aminobenzoic acid, acetamide and isopropanol; the solubilizer is selected from at least one of tween-60, tween-80 and polyoxyethylene hydrogenated castor oil; the emulsifier is at least one selected from stearic acid, glyceryl monostearate, triglycerol monostearate, sucrose fatty acid ester, sucrose acetate isobutyrate, sorbitan tristearate, isopropyl myristate, cholesterol, squalene, squalane, n-butanol, ethylene glycol, ethanol, propylene glycol and polyglycerol ester; the antioxidant is selected from at least one of sulfite, cysteine, di-tert-butyl hydroxy toluene and potassium sorbate; the pH regulator is at least one selected from phosphoric acid buffer solution, triethanolamine, sodium hydroxide, ethylenediamine, laurylamine, sodium bicarbonate and hydrochloric acid; the preservative is selected from at least one of parabens, thimerosal, chlorocresol, trichloro-tert-butanol and benzoic acid and sodium salt thereof; the nocardia rubra cell wall skeleton, the matrix, the propellant, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative are in a weight ratio of 1: (0.1-1000): (0.1-1000): (0.1-7000): (100-10000): (0.1-2000): (0.1-1000): (0.01-30000): (0.1-1000);

or,

in the skin care product, the auxiliary ingredients comprise at least one of a matrix, a humectant, a solvent, an emulsifier, an antioxidant, a pH regulator and a preservative; the matrix is at least one of carbomer, polyethylene glycol, polysorbate, propylene glycol, butylene glycol, hexylene glycol and isopropyl myristate; the humectant is at least one selected from glycerol, sorbitol, mannitol, xylitol, squalane and squalene; the solvent is at least one selected from deionized water, distilled water, ethanol, butanol, pentanol and isopropanol; the emulsifier is at least one selected from vaseline, white oil, silicone oil and lanolin; the antioxidant is at least one selected from sulfite, di-tert-butyl hydroxy toluene and potassium sorbate; the pH regulator is at least one selected from triethanolamine, sodium hydroxide, ethylenediamine, laurylamine, sodium bicarbonate and hydrochloric acid; the preservative is selected from at least one of parabens, propylene glycol, cason, jeep horse power and benzoic acid and its sodium salt; the nocardia rubra cell wall skeleton, the matrix, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative are in a weight ratio of 1: (0.1-1000): (0.1-700): (100-10000): (0.1-2000): (0.1-1000): (0.1-3000): (0.1-1000);

preferably, the first and second electrodes are formed of a metal,

in the pharmaceutical composition, the weight ratio of the nocardia rubra cell wall skeleton, the matrix, the propellant, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative is 1: (20-300): (40-1000): (60-500): (1400-4750): (40-1000): (2-20): (100-2000): (2-30);

or,

in the skin care product, the weight ratio of the nocardia rubra cell wall skeleton, the matrix, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative is 1: (20-300): (60-500): (1400-4750): (40-1000): (2-20): (100-2000): (2-30).

6. The use according to claim 5, wherein, based on the total weight of the pharmaceutical or skin care composition taken as 100%, wherein,

the pharmaceutical composition comprises 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.01-2 wt% of tween-80, 1-4 wt% of isopropyl myristate, 0.01-2 wt% of p-aminobenzoic acid, 0.01-2 wt% of squalene, 0.01-5 wt% of stearic acid, 1-5 wt% of glycerol, 0.1-5 wt% of hexadecanol, 1-10 wt% of tetrafluoroethane, 1-10 wt% of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent;

or the pharmaceutical composition contains 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.5-2 wt% of carbomer, 0.05-2 wt% of tween-80, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 1-8 wt% of glycerol, 1-10 wt% of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent;

or, the pharmaceutical composition comprises 0.02-0.05 wt% nocardia rubra cell wall skeleton, 1-5 wt% white vaseline, 0.1-2 wt% tween-80, 0.01-1 wt% benzoic acid, 0.02-2 wt% sodium sulfite, 1-8 wt% glycerol, 0.01-2 wt% squalene, 1-10 wt% phosphate buffer solution with concentration of 0.1M and pH of 7.2, and balance solvent;

the skin care composition comprises 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 1-8 wt% of glycerol, 3-10 wt% of lanolin, 0.02-2 wt% of squalene, 1-10 wt% of sodium hydroxide solution with the concentration of 1% (W/V) and the balance of solvent;

or the skin care composition contains 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 0.5-2 wt% of carbomer, 3-8 wt% of glycerin, 1-10 wt% of 1% (W/V) sodium hydroxide solution and the balance of solvent;

or, the skin care composition comprises 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 5-10 wt% of lanolin, 0.02-2 wt% of squalene, 10-20 wt% of polysorbate, 1-10 wt% of 1% (W/V) sodium hydroxide solution and the balance of solvent.

7. A pharmaceutical composition or skin care product for treating acne is characterized in that the pharmaceutical composition or skin care product contains nocardia rubra cell wall skeleton and auxiliary components; the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (300-9999); preferably, the weight ratio of the nocardia rubra cell wall skeleton to the auxiliary components is 1: (1999-4999).

8. The pharmaceutical composition or the skin care product according to claim 7, wherein the pharmaceutical composition is in the form of a water agent, an aerosol, a spray, an emulsion, a paste, a gel or a freeze-dried powder; the skin care product is facial cleanser, astringent, essence, lotion or cream.

9. The pharmaceutical composition or skin care product according to claim 7 or 8,

in the pharmaceutical composition, the auxiliary component comprises at least one of a matrix, a propellant, a humectant, a solvent, a solubilizer, an emulsifier, an antioxidant, a pH regulator and a preservative; the matrix is at least one of white vaseline, carbomer, hydroxypropyl methylcellulose, carboxymethylcellulose sodium, chitosan, sucralfate chitosan polyvinylpyrrolidone, polyvinyl alcohol and sodium hyaluronate; the propellant is selected from at least one of dimethyl ether, tetrafluoroethane and hydrofluoroalkane; the humectant is selected from at least one of glycerin and propylene glycol; the solvent is at least one selected from deionized water, distilled water, ethanol, hexadecanol, octadecanol, p-aminobenzoic acid, acetamide and isopropanol; the solubilizer is selected from at least one of tween-60, tween-80 and polyoxyethylene hydrogenated castor oil; the emulsifier is at least one selected from stearic acid, glyceryl monostearate, triglycerol monostearate, sucrose fatty acid ester, sucrose acetate isobutyrate, sorbitan tristearate, isopropyl myristate, cholesterol, squalene, squalane, n-butanol, ethylene glycol, ethanol, propylene glycol and polyglycerol ester; the antioxidant is selected from at least one of sulfite, cysteine, di-tert-butyl hydroxy toluene and potassium sorbate; the pH regulator is at least one selected from phosphoric acid buffer solution, triethanolamine, sodium hydroxide, ethylenediamine, laurylamine, sodium bicarbonate and hydrochloric acid; the preservative is selected from at least one of parabens, thimerosal, chlorocresol, trichloro-tert-butanol and benzoic acid and sodium salt thereof; the nocardia rubra cell wall skeleton, the matrix, the propellant, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative are in a weight ratio of 1: (0.1-1000): (0.1-1000): (0.1-7000): (100-10000): (0.1-2000): (0.1-1000): (0.01-30000): (0.1-1000);

or,

in the skin care product, the auxiliary ingredients comprise at least one of a matrix, a humectant, a solvent, an emulsifier, an antioxidant, a pH regulator and a preservative; the matrix is at least one of carbomer, polyethylene glycol, polysorbate, propylene glycol, butylene glycol, hexylene glycol and isopropyl myristate; the humectant is at least one selected from glycerol, sorbitol, mannitol, xylitol, squalane and squalene; the solvent is at least one selected from deionized water, distilled water, ethanol, butanol, pentanol and isopropanol; the emulsifier is at least one selected from vaseline, white oil, silicone oil and lanolin; the antioxidant is at least one selected from sulfite, di-tert-butyl hydroxy toluene and potassium sorbate; the pH regulator is at least one selected from triethanolamine, sodium hydroxide, ethylenediamine, laurylamine, sodium bicarbonate and hydrochloric acid; the preservative is selected from at least one of parabens, propylene glycol, cason, jeep horse power and benzoic acid and its sodium salt; the nocardia rubra cell wall skeleton, the matrix, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative are in a weight ratio of 1: (0.1-1000): (0.1-700): (100-10000): (0.1-2000): (0.1-1000): (0.1-3000): (0.1-1000)

Preferably, the first and second electrodes are formed of a metal,

in the pharmaceutical composition, the weight ratio of the nocardia rubra cell wall skeleton, the matrix, the propellant, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative is 1: (20-300): (40-1000): (60-500): (1400-4750): (40-1000): (2-20): (100-2000): (2-30);

or,

in the skin care product, the weight ratio of the nocardia rubra cell wall skeleton, the matrix, the humectant, the solvent, the emulsifier, the antioxidant, the pH regulator and the preservative is 1: (20-300): (60-500): (1400-4750): (40-1000): (2-20): (100-2000): (2-30).

10. The pharmaceutical composition or skin care product according to claim 9, wherein, based on the total weight of the pharmaceutical or skin care product composition taken as 100%, wherein,

the pharmaceutical composition comprises 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.01-2 wt% of tween-80, 1-4 wt% of isopropyl myristate, 0.01-2 wt% of p-aminobenzoic acid, 0.01-2 wt% of squalene, 0.01-5 wt% of stearic acid, 1-5 wt% of glycerol, 0.1-5 wt% of hexadecanol, 1-10 wt% of tetrafluoroethane, 1-10 wt% of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent;

or the pharmaceutical composition contains 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.5-2 wt% of carbomer, 0.05-2 wt% of tween-80, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 1-8 wt% of glycerol, 1-10 wt% of phosphoric acid buffer solution with the concentration of 0.1M and the pH value of 7.2 and the balance of solvent;

or, the pharmaceutical composition comprises 0.02-0.05 wt% nocardia rubra cell wall skeleton, 1-5 wt% white vaseline, 0.1-2 wt% tween-80, 0.01-1 wt% benzoic acid, 0.02-2 wt% sodium sulfite, 1-8 wt% glycerol, 0.01-2 wt% squalene, 1-10 wt% phosphate buffer solution with concentration of 0.1M and pH of 7.2, and balance solvent;

the skin care composition comprises 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 1-8 wt% of glycerol, 3-10 wt% of lanolin, 0.02-2 wt% of squalene, 1-10 wt% of sodium hydroxide solution with the concentration of 1% (W/V) and the balance of solvent;

or the skin care composition contains 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 0.5-2 wt% of carbomer, 3-8 wt% of glycerin, 1-10 wt% of 1% (W/V) sodium hydroxide solution and the balance of solvent;

or, the skin care composition comprises 0.02-0.05 wt% of nocardia rubra cell wall skeleton, 0.01-1 wt% of benzoic acid, 0.02-2 wt% of sodium sulfite, 5-10 wt% of lanolin, 0.02-2 wt% of squalene, 10-20 wt% of polysorbate, 1-10 wt% of 1% (W/V) sodium hydroxide solution and the balance of solvent.